Patents by Inventor John Duggan
John Duggan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11735711Abstract: A battery includes a case having a feedthrough port, a feedthrough assembly disposed in the feedthrough port, and a cell stack disposed within the case. The feedthrough port includes an inner conductor and an insulator core separating the inner conductor from the case. The cell stack includes an anode, a cathode, and a separator insulating the anode from the cathode, wherein the anode and cathode are offset from one another. An insulating boot surrounding the cell stack insulates the cell stack from the case. The insulating boot has an opening configured to receive therein the feedthrough assembly, which may include overmolded insulation. The interior surfaces and interior walls of the battery case may be thermal spray-coated with a dielectric material to prevent lithium dendrite formation between cathode and anode surfaces.Type: GrantFiled: February 19, 2021Date of Patent: August 22, 2023Assignee: Pacesetter, Inc.Inventors: Russell Bruch, Joseph Beauvais, Jeffrey Armstrong, Del Charles Brooks, III, Christopher Hallmark, John Duggan
-
Publication number: 20210257601Abstract: The battery includes a container that holds an electrode assembly. The container has an opening that extends from an external side of the container to an internal side of the container. A plug is configured to be inserted into the opening. The plug has a plug taper configured such that a width of the plug decreases linearly from an external side of the plug to an internal side of the plug. The plug taper is present on the plug before the plug is inserted into the opening.Type: ApplicationFiled: August 19, 2020Publication date: August 19, 2021Inventor: John Duggan
-
Publication number: 20210184320Abstract: A battery includes a case having a feedthrough port, a feedthrough assembly disposed in the feedthrough port, and a cell stack disposed within the case. The feedthrough port includes an inner conductor and an insulator core separating the inner conductor from the case. The cell stack includes an anode, a cathode, and a separator insulating the anode from the cathode, wherein the anode and cathode are offset from one another. An insulating boot surrounding the cell stack insulates the cell stack from the case. The insulating boot has an opening configured to receive therein the feedthrough assembly, which may include overmolded insulation. The interior surfaces and interior walls of the battery case may be thermal spray-coated with a dielectric material to prevent lithium dendrite formation between cathode and anode surfaces.Type: ApplicationFiled: February 19, 2021Publication date: June 17, 2021Applicant: Pacesetter, Inc.Inventors: Russell Bruch, Joseph Beauvais, Jeffrey Armstrong, Del Charles Brooks III, Christopher Hallmark, John Duggan
-
Publication number: 20210159470Abstract: The battery has a header positioned in an opening in a case. An electrode is in the case and a terminal is in electrical communication with the electrode through the header. A cured epoxy contacts the case and the terminal such that the epoxy seals the opening in the case. The header is located between the electrodes and the epoxy. The header can exclude a glass-to-metal seal.Type: ApplicationFiled: November 13, 2020Publication date: May 27, 2021Inventors: John Duggan, Timothy R. Marshall, Steven Davis
-
Patent number: 10964922Abstract: A battery includes a case having a feedthrough port, a feedthrough assembly disposed in the feedthrough port, and a cell stack disposed within the case. The feedthrough port includes an inner conductor and an insulator core separating the inner conductor from the case. The cell stack includes an anode, a cathode, and a separator insulating the anode from the cathode, wherein the anode and cathode are offset from one another. An insulating boot surrounding the cell stack insulates the cell stack from the case. The insulating boot has an opening configured to receive therein the feedthrough assembly, which may include overmolded insulation. The interior surfaces and interior walls of the battery case may be thermal spray-coated with a dielectric material to prevent lithium dendrite formation between cathode and anode surfaces.Type: GrantFiled: December 27, 2018Date of Patent: March 30, 2021Assignee: Pacesetter, Inc.Inventors: Del Charles Brooks, III, Christopher Hallmark, John Duggan, Jeffrey Armstrong
-
Patent number: 10727454Abstract: A battery includes a case having a feedthrough port, a feedthrough assembly disposed in the feedthrough port, and a cell stack disposed within the case. The feedthrough port includes an inner conductor and an insulator core separating the inner conductor from the case. The cell stack includes an anode, a cathode, and a separator insulating the anode from the cathode, wherein the anode and cathode are offset from one another. An insulating boot surrounding the cell stack insulates the cell stack from the case. The insulating boot has an opening configured to receive therein the feedthrough assembly, which may include overmolded insulation. The interior surfaces and interior walls of the battery case may be thermal spray-coated with a dielectric material to prevent lithium dendrite formation between cathode and anode surfaces.Type: GrantFiled: November 16, 2017Date of Patent: July 28, 2020Assignee: Pacesetter, Inc.Inventors: Russell Bruch, Joseph Beauvais, Jeffrey Armstrong, Del Charles Brooks, III, Christopher Hallmark, John Duggan
-
Publication number: 20190131593Abstract: A battery includes a case having a feedthrough port, a feedthrough assembly disposed in the feedthrough port, and a cell stack disposed within the case. The feedthrough port includes an inner conductor and an insulator core separating the inner conductor from the case. The cell stack includes an anode, a cathode, and a separator insulating the anode from the cathode, wherein the anode and cathode are offset from one another. An insulating boot surrounding the cell stack insulates the cell stack from the case. The insulating boot has an opening configured to receive therein the feedthrough assembly, which may include overmolded insulation. The interior surfaces and interior walls of the battery case may be thermal spray-coated with a dielectric material to prevent lithium dendrite formation between cathode and anode surfaces.Type: ApplicationFiled: December 27, 2018Publication date: May 2, 2019Applicant: Pacesetter, Inc.Inventors: Del Charles Brooks, III, Christopher Hallmark, John Duggan, Jeffrey Armstrong
-
Publication number: 20180138463Abstract: A battery includes a case having a feedthrough port, a feedthrough assembly disposed in the feedthrough port, and a cell stack disposed within the case. The feedthrough port includes an inner conductor and an insulator core separating the inner conductor from the case. The cell stack includes an anode, a cathode, and a separator insulating the anode from the cathode, wherein the anode and cathode are offset from one another. An insulating boot surrounding the cell stack insulates the cell stack from the case. The insulating boot has an opening configured to receive therein the feedthrough assembly, which may include overmolded insulation. The interior surfaces and interior walls of the battery case may be thermal spray-coated with a dielectric material to prevent lithium dendrite formation between cathode and anode surfaces.Type: ApplicationFiled: November 16, 2017Publication date: May 17, 2018Applicant: Pacesetter, Inc.Inventors: Russell Bruch, Joseph Beauvais, Jeffrey Armstrong, Del Charles Brooks, III, Christopher Hallmark, John Duggan
-
Patent number: 9668718Abstract: A tissue removal apparatus and needle assembly for extracting a tissue portion from tissue or the like, the needle assembly comprising an inner tube having an interior cavity, an outer cannula having a proximal end, a distal end and an interior cavity, the interior cavity of the outer cannula having an interior diameter to slidably receive the inner tube and a collapsible section operably engaged with the inner tube and the outer cannula whereby a forward movement of a portion of the inner tube within the interior cavity of the outer cannula changes the collapsible section from a neutral position to a collapsed position to engage the tissue portion. In some embodiments, the outer cannula further comprises an aperture configured to allow a tissue portion from within the needle assembly to pass through or otherwise be expelled outside of the needle assembly.Type: GrantFiled: June 19, 2016Date of Patent: June 6, 2017Assignee: Theragenics CorporationInventors: John Duggan, Hugh Tripp, Thomas Johnson
-
Publication number: 20160324508Abstract: A tissue removal apparatus and needle assembly for extracting a tissue portion from tissue or the like, the needle assembly comprising an inner tube having an interior cavity, an outer cannula having a proximal end, a distal end and an interior cavity, the interior cavity of the outer cannula having an interior diameter to slidably receive the inner tube and a collapsible section operably engaged with the inner tube and the outer cannula whereby a forward movement of a portion of the inner tube within the interior cavity of the outer cannula changes the collapsible section from a neutral position to a collapsed position to engage the tissue portion. In some embodiments, the outer cannula further comprises an aperture configured to allow a tissue portion from within the needle assembly to pass through or otherwise be expelled outside of the needle assembly.Type: ApplicationFiled: June 19, 2016Publication date: November 10, 2016Applicant: Theragenics CorporationInventors: John Duggan, Hugh Tripp, Thomas Johnson
-
Publication number: 20120141511Abstract: A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E, linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain, which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome; Domain T is the Translocation Domain, which translocates the agent from within the endosome across the endosomal membrane into the cytosol of the cell; and Domain E is the Effector Domain, which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: ApplicationFiled: October 11, 2011Publication date: June 7, 2012Inventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 8158132Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: GrantFiled: September 26, 2005Date of Patent: April 17, 2012Assignee: Syntaxin LimitedInventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 7892560Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: GrantFiled: June 28, 2007Date of Patent: February 22, 2011Assignee: Syntaxin, LtdInventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 7887810Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: GrantFiled: June 28, 2007Date of Patent: February 15, 2011Assignee: Syntaxin, LtdInventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 7611805Abstract: An electrochemical cell comprising a cathode of a powder material pressed into intimate contact with a rod-shaped current collector and an anode at least partially wrapped around the cathode is described. The cathode current collector is preferably provided with a plurality of offset flats offset with respect to each other. This helps prevent the cathode active material from sliding off of the rod-shaped current collector. The anode has spaced apart edges at opposite ends of its width that form a gap with the anode wrapped around the cathode. This helps in sliding the anode/cathode electrode assembly into a cylindrical tube comprising the cell casing. A preferred chemistry is a lithium/CFx activated with a nonaqueous electrolyte.Type: GrantFiled: August 30, 2005Date of Patent: November 3, 2009Assignee: Greatbatch Ltd.Inventors: Dominick Frustaci, Donald Kaiser, Paul Hallifax, John Duggan, Kenneth Moceri
-
Publication number: 20090131645Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: ApplicationFiled: June 28, 2007Publication date: May 21, 2009Inventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Publication number: 20080319167Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: ApplicationFiled: June 28, 2007Publication date: December 25, 2008Inventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 7452543Abstract: A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.Type: GrantFiled: October 25, 2005Date of Patent: November 18, 2008Assignee: Syntaxin Ltd.Inventors: John Andrew Chaddock, Philip Marks, Michael John Duggan
-
Patent number: 7388463Abstract: An electromagnetic coil assembly comprising a spool-spindle and a case. The spool-spindle comprises a spindle portion and a larger included portion. The spindle portion has a conductor wound thereon. The larger included portion has opening for receiving the conductor. The case has a first case end and a second case end, with an opening extending through the case. A first internal surrounding surface extends from the second case end and a second surrounding internal surface having a smaller diameter extends from the first case end. The first internal surrounding surface meets the second internal surrounding surface at an annular internal wall. The spool-spindle is positioned in the case until the larger include portion abuts against the annular internal wall, and the case and spool-spindle are joined.Type: GrantFiled: February 1, 2005Date of Patent: June 17, 2008Assignee: Infusion Systems, LLCInventors: John Duggan, Norbert W. Frenz, Jr.
-
Publication number: 20070117021Abstract: an electrochemical cell comprising a cathode of a powder material pressed into intimate contact with a rod-shaped current collector and an anode at least partially wrapped around the cathode is described. The cathode current collector is preferably provided with a plurality of offset flats offset with respect to each other. This helps prevent the cathode active material from sliding off of the rod-shaped current collector. The anode has spaced apart edges at opposite ends of its width that form a gap with the anode wrapped around the cathode. This helps in sliding the anode/cathode electrode assembly into a cylindrical tube comprising the cell casing. A preferred chemistry is a lithium/CFx activated with a nonaqueous electrolyte.Type: ApplicationFiled: August 30, 2005Publication date: May 24, 2007Inventors: Dominick Frustaci, Donald Kaiser, Paul Hallifax, John Duggan, Kenneth Moceri